Exploratory analysis–secondary outcome measures MCID
Anxiety, anxiety, depression, Depression, WL
SECONDARY
Changes in MCID on secondary outcome measures were explored to determine which variables may be useful for a definitive trial. HADS-Depression and HADS-Anxiety MCID changes are presented in Fig. Visualisations of participant-level change scores from Time 1 to Time 2 on the Hospital Anxiety and Depression Scale (HADS), not including those who withdrew. HADS-Depression change scores are on the top row, and HADS-Anxiety scores are in the bottom row. Dashed lines indicate the minimal clinically important difference (HADS-Depression = 1.96, HADS-Anxiety = 1.83) in either direction. Lower change scores indicate greater reductions in depression and anxiety. Percentages indicate numbers of those within in each group who made MCID improvements on either measure from Time 1 to Time 2Across five imputed datasets, AP participants had a MCID improvement range of 51.72–58.62%, versus AE (range 57.14–64.28%), and WL (18.75% across all five imputations) on HADS-Depression. For HADS-Anxiety, the imputed range was 51.72–55.17% for AP, versus AE (range 21.42–28.57%), and WL (range 18.75–31.25%).Complete case MCID improvements on study measures from Time 1 to Time 2 are in Additional File 